| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 585 | - | - | 982 | 7.492 | 5.680 | 2.209 | 0 | 0 | 0 |
| Total Income - EUR | 585 | - | - | 982 | 7.492 | 5.680 | 2.209 | 15.289 | 0 | 0 |
| Total Expenses - EUR | 2.781 | - | - | 2.470 | 3.303 | 2.347 | 1.151 | 16.703 | 0 | 0 |
| Gross Profit/Loss - EUR | -2.196 | - | - | -1.487 | 4.189 | 3.332 | 1.057 | -1.414 | 0 | 0 |
| Net Profit/Loss - EUR | -2.214 | - | - | -1.517 | 3.964 | 3.162 | 991 | -1.872 | 0 | 0 |
| Employees | 1 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Aetel Biotech Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 23.483 | - | - | 23.986 | 28.076 | 28.167 | 20.685 | 1.186 | 0 | 0 |
| Inventories | 20.923 | - | - | 19.618 | 19.548 | 17.319 | 16.244 | 0 | 0 | 0 |
| Receivables | 2.548 | - | - | 3.376 | 7.007 | 5.721 | 3.015 | 0 | 0 | 0 |
| Cash | 12 | - | - | 992 | 1.521 | 5.126 | 1.426 | 1.186 | 0 | 0 |
| Shareholders Funds | -10.505 | - | - | -11.041 | -6.864 | -3.572 | -2.501 | -4.381 | -4.368 | -4.344 |
| Social Capital | 45 | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 33.890 | - | - | 35.027 | 34.940 | 31.738 | 23.187 | 5.567 | 4.368 | 4.344 |
| Income in Advance | 98 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4617 - 4617" | |||||||||
| CAEN Financial Year |
4617
|
|||||||||
Comments - Aetel Biotech Srl